Metformina + Sitagliptina Blixie

Metformin Hydrochloride and Sitagliptin, the active ingredients in Metformina + Sitagliptina Blixie, are a Biguanide and DPP‑4 inhibitor combination presented as an oral tablet for systemic use. They are employed to improve glycemic control in adults with type 2 diabetes mellitus by reducing hepatic glucose production and enhancing insulin secretion.

GNH USA supplies Metformina + Sitagliptina Blixie as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements to ensure product integrity.

Metformina + Sitagliptina Blixie is used in the management of type 2 diabetes mellitus, acting on multiple glucose‑regulating pathways.

- Type 2 diabetes mellitus (inadequate control with metformin alone): provides additional HbA1c reduction when added to diet and exercise. - Type 2 diabetes mellitus (as initial therapy when metformin is contraindicated): offers glucose‑lowering effect via complementary mechanisms. - Type 2 diabetes mellitus (as adjunct to other antidiabetic agents): enhances overall glycemic control in combination regimens.

Metformina + Sitagliptina Blixie may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Abdominal discomfort: cramping or pain. - Headache: mild tension‑type headache. - Upper respiratory tract infection: cold‑like symptoms. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas. - Hepatic dysfunction: abnormal liver enzymes. - Skin reactions: rash or hypersensitivity. - Renal impairment worsening: decline in kidney function.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Renal function assessment: evaluate eGFR and avoid use in severe renal impairment. - Lactic acidosis risk: contraindicated in patients with conditions predisposing to hypoxia. - Hypoglycemia monitoring: especially when used with insulin or sulfonylureas. - Pregnancy and lactation: discuss risks and benefits with a healthcare provider. - Drug interaction review: assess concomitant medications for additive effects. - Store at ambient temperature: keep in the original pack, protect from moisture.

Metformina + Sitagliptina Blixie can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of severe hypoglycemia. - Iodinated contrast agents: may precipitate lactic acidosis in renal‑impaired patients. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): may raise metformin plasma levels.

Moderate Interactions (Monitor Closely): - Diuretics: can affect renal clearance of metformin. - ACE inhibitors or ARBs: may further reduce renal function. - Beta‑blockers: may mask hypoglycemia symptoms. - Oral corticosteroids: may increase blood glucose, requiring dose adjustment.